Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 cross-tumor trial of crizotinib in ALK- or MET-altered advanced tumors
2011-001988-52Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizotinib in anaplastic large cell lymphoma (ALCL), inflammatory pseudotumor (IPT), papillary renal cell carcinoma (PRCC) and 4 more, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Objective response rate by RECIST 1.1. Started Jun 2012; status: completed.
02
Drugs
crizotinib
03
Conditions
anaplastic large cell lymphoma (ALCL)inflammatory pseudotumor (IPT)papillary renal cell carcinoma (PRCC)alveolar soft part sarcoma (ASPS)clear cell sarcoma (CCS)
Beyond the preview
Go deeper on 2011-001988-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001988-52.